Chiron Investment Management LLC Purchases Shares of 63,629 Boston Scientific Co. (NYSE:BSX)

Chiron Investment Management LLC bought a new position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 63,629 shares of the medical equipment provider's stock, valued at approximately $5,683,000. Boston Scientific makes up 1.9% of Chiron Investment Management LLC's portfolio, making the stock its 19th largest position.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Sunbelt Securities Inc. increased its stake in Boston Scientific by 16.6% in the 3rd quarter. Sunbelt Securities Inc. now owns 1,414 shares of the medical equipment provider's stock worth $118,000 after purchasing an additional 201 shares during the period. M&T Bank Corp lifted its position in Boston Scientific by 0.3% in the 3rd quarter. M&T Bank Corp now owns 106,127 shares of the medical equipment provider's stock valued at $8,894,000 after acquiring an additional 370 shares in the last quarter. Passumpsic Savings Bank bought a new stake in shares of Boston Scientific in the third quarter worth approximately $3,015,000. World Investment Advisors LLC grew its holdings in shares of Boston Scientific by 50.9% in the third quarter. World Investment Advisors LLC now owns 11,684 shares of the medical equipment provider's stock worth $979,000 after acquiring an additional 3,939 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Boston Scientific in the third quarter worth approximately $1,175,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the company. StockNews.com downgraded Boston Scientific from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. Argus set a $130.00 price target on shares of Boston Scientific in a report on Tuesday, February 18th. Raymond James upped their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 6th. Morgan Stanley upped their price target on Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Finally, Barclays lifted their price target on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $110.22.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares in the company, valued at $560,103.60. This trade represents a 75.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP John Bradley Sorenson sold 6,528 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $104.97, for a total value of $685,244.16. Following the completion of the sale, the executive vice president now directly owns 26,449 shares in the company, valued at $2,776,351.53. This trade represents a 19.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 133,183 shares of company stock valued at $13,948,476 in the last three months. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Performance

Shares of NYSE BSX traded down $0.17 during midday trading on Friday, hitting $95.08. The company's stock had a trading volume of 6,672,959 shares, compared to its average volume of 6,370,413. The firm has a market cap of $140.63 billion, a P/E ratio of 76.06, a P/E/G ratio of 2.79 and a beta of 0.73. The firm's fifty day moving average price is $99.68 and its 200-day moving average price is $94.26. Boston Scientific Co. has a 1-year low of $66.80 and a 1-year high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.